NASDAQ:EQRX EQRx (EQRX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.34▼$2.3450-Day Range$2.04▼$2.4752-Week Range$1.58▼$5.55VolumeN/AAverage Volume3.30 million shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get EQRx alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About EQRx Stock (NASDAQ:EQRX)EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.Read More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here EQRX Stock News HeadlinesMay 7, 2024 | finance.yahoo.com599 Cancer Monoclonal Antibody Collaboration and Licensing Deals Report and Directory 2016-2024February 28, 2024 | finance.yahoo.comRevolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call TranscriptJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.February 27, 2024 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate ProgressFebruary 26, 2024 | uk.finance.yahoo.comRevolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical ProgressFebruary 21, 2024 | msn.comAbCellera Biologics (ABCL) Q4 2023 Earnings Call TranscriptFebruary 1, 2024 | morningstar.comGubra AS GUBRANovember 14, 2023 | msn.comSoftBank adds stakes in Neumora, Globalstar in Q3; stake in WeWork slashedJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 9, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines and EQRx Stockholders Approve EQRx AcquisitionNovember 9, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Completes Acquisition of EQRxNovember 8, 2023 | msn.comRevolution Medicines and EQRx stockholders approves acquisitionNovember 7, 2023 | finanznachrichten.deRevolution Medicines, Inc.: Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate ProgressNovember 2, 2023 | finance.yahoo.comWe're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash WiselyOctober 20, 2023 | barrons.comCalling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesOctober 8, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, NEWR, EQRX, SCUSeptember 27, 2023 | benzinga.comEQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of ShareholdersSeptember 26, 2023 | finance.yahoo.comApplied BioMath, LLC Hosts 6th Annual Quantitative Systems Pharmacology SummitSee More Headlines Receive EQRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:EQRX CUSIPN/A CIK1843762 Webiii.cmlifesciencesspac.com Phone617-315-2255FaxN/AEmployees362Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-169,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.33% Return on Assets-19.32% Debt Debt-to-Equity RatioN/A Current Ratio18.77 Quick Ratio22.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book0.98Miscellaneous Outstanding Shares487,420,000Free Float398,218,000Market Cap$1.14 billion OptionableOptionable Beta0.48 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Alexis A. Borisy A.M. (Age 51)Founder & Executive Chairman of Board of Directors Ms. Melanie I. Nallicheri (Age 54)President, CEO, Principal Executive & Financial Officer and Director Comp: $931.75kMs. Dina Ciarimboli J.D. (Age 54)General Counsel & Corporate Secretary Comp: $628.63kMr. Robert Forrester LL.B. (Age 59)Co-Founder & Advisor Dr. Peter B. Bach M.D. (Age 58)MAPP, Co-Founder & Advisor Sir Andrew Dillon CBECo-Founder & AdvisorMr. Daniel Hoey (Age 56)Chief of Technical Operations Ms. Rona Anhalt (Age 58)Chief People Officer Dr. Carlos Garcia-Echeverria Ph.D. (Age 58)Chief of RX Creation Dr. Eric E. Hedrick M.D. (Age 58)Chief Physician Executive Comp: $575.1kMore ExecutivesKey CompetitorsLianBioNASDAQ:LIANPHAXIAM TherapeuticsNASDAQ:PHXMPolarityTENASDAQ:PTEIQ9 Meters BiopharmaNASDAQ:NMTRHumanigenNASDAQ:HGENView All Competitors This page (NASDAQ:EQRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EQRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EQRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.